Vera Therapeutics, Inc. (VERA) — Insider Trading

AI-Powered SEC Filing Analysis

Latest Insider Trading Filed: 2026-04-15

Key Insights

The filing indicates that the CEO, Marshall Fordyce, has sold a significant amount of Vera Therapeutics' Class A common stock, totaling over 22,000 shares. This may raise concerns about management's confidence in the company's near-term prospects.
The shares were sold pursuant to a 10b5-1 trading plan, suggesting the transactions were pre-planned and not necessarily driven by new information. However, the timing and magnitude of the sales could still be viewed negatively by investors.
The CEO still holds a substantial number of shares, both directly and indirectly through a trust and a GRAT, indicating he maintains a significant ownership stake in the company. This may help mitigate concerns about the insider selling.

Want the newest filings?

This analysis covers the filing from 2026-04-15. New 10-K, 10-Q and 8-K filings are analyzed the moment they are released — exclusively in the app.

Download on the App Store Open in app →

Earlier Insider Trading filings

Filed: 2026-03-25

Jane Wright-Mitchell, the Chief Legal Officer of Vera Therapeutics, Inc. (VERA), acquired 42,403 shares of Class A Common Stock through restricted stock units (RSUs), indicating her commitment to the company.
Wright-Mitchell also received a stock option to purchase 56,850 shares of Class A Common Stock, further aligning her interests with those of the company and its shareholders.
The vesting schedules for both the RSUs and the stock option suggest a long-term focus, with the RSUs vesting over 4 years and the stock option vesting over 9 years, indicating Wright-Mitchell's belief in the company's long-term potential.

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.